Haleon (HLN) Revenue (2021 - 2025)

Haleon's (HLN) quarterly Revenue came in at $7.3 billion in Q4 2025, down 30.7% on a QoQ basis from $10.6 billion in Q4 2023.

Haleon (HLN) Revenue (2021 - 2025) Analysis & Trends

Haleon (HLN) has 4 years of Revenue data on file, last reported at $7.3 billion in Q4 2025.

Quarterly Revenue changed N/A year-over-year to $7.3 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $25.0 billion (changed N/A YoY) and the FY2025 annual result came in at $14.7 billion, up 2.18% from the prior year.
Revenue fell to $7.3 billion in Q4 2025, from $10.6 billion in the prior quarter.
In the past five years, Revenue ranged from a high of $10.6 billion in Q4 2023 to a low of $3.1 billion in Q4 2022.
A 4-year average of $6.3 billion and a median of $5.5 billion in 2025 frame the typical range for Revenue.
Annual changes were most pronounced in 2022 — Revenue slumped 67.65% — and 2023, when it surged 243.83%.
Tracing HLN's Revenue over 4 years: stood at $9.5 billion in 2021, then plunged by 67.65% to $3.1 billion in 2022, then surged by 243.83% to $10.6 billion in 2023, then slumped by 30.7% to $7.3 billion in 2025.
The last three Revenue figures came in at $7.3 billion (Q4 2025), $10.6 billion (Q4 2023), and $3.4 billion (Q2 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Haleon	86.50 Bn	85.53 Bn	-	-
2	Teva Pharmaceutical Industries	42.71 Bn	39.05 Bn	2.15 Bn	4.14 Bn
3	Zoetis	30.86 Bn	29.18 Bn	1.80 Bn	2.47 Bn
4	Takeda Pharmaceutical	28.50 Bn	22.70 Bn	5.10 Bn	7.65 Bn
5	United Therapeutics	22.06 Bn	19.40 Bn	683.80 Mn	783.30 Mn
6	Viatris	18.84 Bn	17.95 Bn	1.46 Bn	3.76 Bn
7	Neurocrine Biosciences	15.55 Bn	15.16 Bn	935.80 Mn	959.00 Mn
8	Vireo Growth	11.86 Bn	11.71 Bn	59.30 Mn	106.20 Mn
9	Elanco Animal Health	11.77 Bn	11.24 Bn	798.00 Mn	1.37 Bn
10	HUTCHMED (China)	10.92 Bn	9.54 Bn	-	-

Download Data